|
1
|
Ahmed KM, Cao N and Li JJ: HER-2 and
NF-kappaB as the targets for therapy-resistant breast cancer.
Anticancer Res. 26:4235–4243. 2006.PubMed/NCBI
|
|
2
|
Jin Q and Esteva FJ: Cross-talk between
the ErbB/HER family and the type I insulin-like growth factor
receptor signaling pathway in breast cancer. J Mammary Gland Biol
Neoplasia. 13:485–498. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney
N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, Aydiner A and Topuz
E: Lower level of MAPK expression is associated with anthracycline
resistance and decreased survival in patients with hormone receptor
negative breast cancer. Cancer Invest. 26:671–679. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burris H and Rocha-Lima C: New therapeutic
directions for advanced pancreatic cancer: targeting the epidermal
growth factor and vascular endothelial growth factor pathways.
Oncologist. 13:289–298. 2008. View Article : Google Scholar
|
|
5
|
Duneau JP, Vegh AP and Sturgis JN: A
dimerization hierarchy in the transmembrane domains of the HER
receptor family. Biochemistry. 46:2010–2019. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zaczek A, Brandt B and Bielawski KP: The
diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine
kinase receptors and the consequences for therapeutic approaches.
Histol Histopathol. 20:1005–1015. 2005.PubMed/NCBI
|
|
7
|
Yokoyama H, Ikehara Y, Kodera Y, Ikehara
S, Yatabe Y, Mochizuki Y, Koike M, Fujiwara M, Nakao A, Tatematsu M
and Nakanishi H: Molecular basis for sensitivity and acquired
resistance to gefitinib in HER2-overexpressing human gastric cancer
cell lines derived from liver metastasis. Br J Cancer.
95:1504–1513. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pratilas CA, Hanrahan AJ, Halilovic E, et
al: Genetic predictors of MEK dependence in non-small cell lung
cancer. Cancer Res. 68:9375–9383. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
De Graeff P, Crijns AP, ten Hoor KA, Klip
HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries
EG, de Jong S and van der Zee AG: The ErbB signalling pathway:
protein expression and prognostic value in epithelial ovarian
cancer. Br J Cancer. 99:341–349. 2008.PubMed/NCBI
|
|
10
|
Kim KK, Lee JJ, Yang Y and Lee JH:
Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the
transactivation of ErbB2 in human breast and gastric cancer cells.
Carcinogenesis. 29:704–712. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim SY, Kim HP, Kim YJ, Oh do Y, Im SA,
Lee D, Jong HS, Kim TY and Bang YJ: Trastuzumab inhibits the growth
of human gastric cancer cell lines with HER2 amplification
synergistically with cisplatin. Int J Oncol. 32:89–95.
2008.PubMed/NCBI
|
|
12
|
Inui T, Asakawa A, Morita Y, Mizuno S,
Natori T, Kawaguchi A, Murakami M, Hishikawa Y and Inui A: HER-2
overexpression and targeted treatment by trastuzumab in a very old
patient with gastric cancer. J Intern Med. 260:484–487. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ,
Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and
Meyerson M: EGFR mutations in lung cancer: correlation with
clinical response to gefitinib therapy. Science. 304:1497–1500.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and
Haber DA: Activating mutations in the epidermal growth factor
receptor underlying responsiveness of non-small cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee JW, Soung YH, Seo SH, Kim SY, Park CH,
Wang YP, Park K, Nam SW, Park WS, Kim SH, Lee JY, Yoo NJ and Lee
SH: Somatic mutations of ERBB2 kinase domain in gastric, colorectal
and breast carcinomas. Clin Cancer Res. 12:57–61. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Akiyama T, Sudo C and Ogawara H: The
product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein
with tyrosine kinase activity. Science. 232:1644–1646. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tokunaga A, Onda M, Okuda T, Teramoto T,
Fujita I, Mizutani T, Kiyama T, Yoshiyuki T, Nishi K and Matsukura
N: Clinical significance of epidermal growth factor (EGF), EGF
receptor and c-erbB-2 in human gastric cancer. Cancer.
75:1418–1425. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yano T, Doi T, Ohtsu A, Boku N, Hashizume
K, Nakanishi M and Ochiai A: Comparison of HER2 gene amplification
assessed by fluorescence in situ hybridization and HER2
protein expression assessed by immunohistochemistry in gastric
cancer. Oncol Rep. 15:65–71. 2006.PubMed/NCBI
|
|
19
|
Bulanov D: Gastric cancer – current state
of the problem. Part I. Epidemiology. Pathology. Classification.
Staging. Khirurgiia (Sofia). 4:48–59. 2007.
|
|
20
|
Lordick F, Bang YJ and Kang YK:
HER2-positive advanced gastric cancer: similar HER2-positivity
levels to breast cancer. Eur J Cancer. 5:2712007. View Article : Google Scholar
|
|
21
|
Cooperative Study Group of HER2 in China.
Multicenter study on HER-2/neu gene amplification and protein
expression in patients with gastric cancer. Chin J Dig. 26:657–660.
2006.
|
|
22
|
Tateishi M, Toda T, Minamisono Y and
Nagasaki S: Clinicopathological significance of c-erbB-2 protein
expression in human gastric carcinoma. Surg Oncol. 49:209–212.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sasano H, Date F, Imatani A, Asaki S and
Nagura H: Double immunostaining for c-erbB-2 and p53 in human
stomach cancer cells. Hum Pathol. 24:584–589. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chia S, Norris B, Speers C, Cheang M,
Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO and Gelmon K:
Human epidermal growth factor receptor 2 overexpression as a
prognostic factor in a large tissue microarray series of
node-negative breast cancers. J Clin Oncol. 26:5697–5704. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Okegawa T, Kinjo M, Nutahara K and
Higashihara E: Pretreatment serum level of HER2/nue as a prognostic
factor in metastatic prostate cancer patients about to undergo
endocrine therapy. Int J Urol. 13:1197–1201. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Soung YH, Lee JW, Kim SY, Wang YP, Jo KH,
Moon SW, Park WS, Nam SW, Lee JY, Yoo NJ and Lee SH: Somatic
mutations of the ERBB4 kinase domain in human cancers. Int J
Cancer. 118:1426–1429. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stephens P, Hunter C, Bignell G, et al:
Lung cancer: intragenic ERBB2 kinase mutations in tumors. Nature.
431:525–526. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shigematsu H, Takahashi T, Nomura M,
Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S,
Shimizu N, Fujisawa T, Minna JD and Gazdar AF: Somatic mutations of
the HER2 kinase domain in lung adenocarcinomas. Cancer Res.
65:1642–1626. 2005. View Article : Google Scholar : PubMed/NCBI
|
